Which hedge funds own REGN? REGENERON PHARMACEUTICALS, Q2 2026 13F holders
Healthcare · Open on the interactive board
12 of the hedge funds tracked by WhaleCreep disclosed a position in REGN (REGENERON PHARMACEUTICALS) in their Q2 2026 13F filings, worth $474.3m in total. The largest holder by portfolio weight is Bronte Capital at 11.4% of its book.
12tracked managers holding
0opened this quarter
0exited this quarter
Which hedge funds hold REGN? Current holders by portfolio weight
| Manager | As of | Weight of book | Value | Shares | Δ shares | Action |
|---|---|---|---|---|---|---|
| Bronte Capital | Q2 2026 | 11.4% | $101.4m | 162,618 | -6% | reduced |
| Southeastern Asset Management | Q2 2026 | 5.1% | $24.3m | 152,322 | 17% | added |
| Woodline Partners | Q2 2026 | 0.1% | $45.3m | 72,595 | 7% | added |
| Bridgewater Associates | Q2 2026 | 0.1% | $32.0m | 51,333 | 126% | added |
| Renaissance Technologies LLC | Q2 2026 | 0.1% | $92.4m | 148,222 | 122% | added |
| Millennium Management | Q2 2026 | 0.1% | $103.0m | 165,120 | 163% | added |
| Citadel Advisors | Q2 2026 | 0.0% | $35.9m | 57,604 | 21% | added |
| Brevan Howard Capital Management | Q2 2026 | 0.0% | $1.2m | 1,979 | 493% | added |
| D. E. Shaw & Co | Q2 2026 | 0.0% | $24.0m | 38,477 | 69% | added |
| Marshall Wace | Q2 2026 | 0.0% | $14.3m | 23,000 | 6416% | added |
| Horizon Kinetics | Q2 2026 | 0.0% | $402.2k | 645 | -4% | reduced |
| Ancora Advisors | Q2 2026 | 0.0% | $39.3k | 63 | -40% | reduced |
Held in a manager's last filing on record
These managers have not filed for the latest quarter; their last disclosure is dated.
| Manager | Last filing | Weight |
|---|---|---|
| Caxton Associates | Q4 2024 | 0.0% |
How has hedge fund ownership of REGN changed?
| Quarter | Managers holding | Combined value |
|---|---|---|
| Q2 2026 | 12 | $474.3m |
| Q1 2026 | 13 | $397.6m |
| Q4 2025 | 10 | $877.8m |
| Q3 2025 | 10 | $674.3m |
| Q2 2025 | 10 | $368.1m |
| Q1 2025 | 10 | $432.6m |
| Q4 2024 | 9 | $405.4m |
| Q3 2024 | 10 | $565.2m |
| Q2 2024 | 11 | $628.3m |
| Q1 2024 | 11 | $697.9m |
| Q4 2023 | 13 | $1,000.0m |
| Q3 2023 | 11 | $613.0m |
| Q2 2023 | 10 | $413.6m |
| Q1 2023 | 12 | $601.6m |
| Q4 2022 | 10 | $461.1m |
| Q3 2022 | 9 | $499.1m |
Counts every tracked manager that disclosed REGN in that quarter's filing, including managers that have since stopped filing.